Brimonidine Tartrate

The recommended dosage of Alphagan P is one drop in the affected eye(s) three times daily after a gap of 8 hours each.

Brimonidine Tartrate 0.1% (1.0 mg/mL) or 0.15% (1.5 mg/mL).
Inactives: sodium carboxymethylcellulose; sodium borate; boric acid;
sodium chloride; potassium chloride; calcium chloride; magnesium
chloride; Purite® 0.005% (0.05mg/mL) as a preservative; purified water;

• Patients with severe cardiovascular disease should exercise caution while taking Alphagan P.
• ALPHAGAN P has not been studied in patients with hepatic or renal
• impairment.Such patients should be treated with caution.
• In Patients with depression, cerebral or coronary insufficiency,Raynaud?s phenomenon, orthostatic hypotension or thromboangiitis obliterans, ALPHAGAN P should be used with caution. Patients who are prescribed IOP-lowering medication should be kept under continous monitoring for IOP.
• For nuring mothers it should be decided whether to discontinue nursing or to discontinue the drug, depending upon the importance of the drug to the mother.

• ALPHAGAN P may cause fatigue and drowsiness in some patients.
• Patients who are involved in hazardous activities should be cautious about the chances of decrease in mental alertness.
• Other cautions of using Alphagan P include: bradycardia; depression; iritis; keratoconjunctivitis sicca; miosis; nausea; skin reactions (including erythema, eyelid pruritus, rash, and vasodilation) and tachycardia.
• Apnea; bradycardia; hypotension; hypothermia; hypotonia; and somnolence have been reported in infants receiving brimonidine tartrate ophthalmic solutions.
• Adverse effects of Alphagan P include allergic reaction, asthenia, blepharitis, blepharoconjunctivitis, blurred vision, bronchitis,
• cataract, conjunctival edema, conjunctival hemorrhage, conjunctivitis,
• cough, dizziness, dyspepsia, dyspnea, epiphora, eye discharge, eye
• dryness, eye irritation, eye pain, eyelid edema, eyelid erythema, fatigue, flu syndrome, follicular conjunctivitis, foreign body sensation, gastrointestinal disorder, headache, hypercholesterolemia, hypotension, infection (primarily colds and respiratory infections), insomnia, keratitis, lid disorder, pharyngitis, photophobia,rash, rhinitis, sinus infection, sinusitis, somnolence, stinging, superficial punctate keratopathy, tearing, visual field defect, vitreous detachment, vitreous disorder, vitreous floaters, and worsened visual acuity.

ALPHAGAN P (brimonidine tartrate ophthalmic solution) is a relatively
selective alpha-2 adrenergic agonist for ophthalmic use.
It comes in 2 forms :

• Off-white to pale yellow powder.


• In solution form, ALPHAGAN P (brimonidine tartrate ophthalmic solution) has a clear, greenish-yellow color.

• Active ingredient: brimonidine tartrate 0.1% (1.0 mg/mL) or 0.15%
  (1.5 mg/mL).


• Inactives: sodium carboxymethylcellulose; sodium borate; boric acid;
  sodium chloride; potassium chloride; calcium chloride; magnesium
  chloride; Purite® 0.005% (0.05mg/mL) as a preservative; purified water;
  with hydrochloric acid and/or sodium hydroxide to adjust pH.

The recommended dosage is one drop of ALPHAGAN P in the affected
eyes three times daily, approximately 8 hours apart.
If more than one topical ophthalmic product is being used, the products should be used at least 5 minutes apart.